215 related articles for article (PubMed ID: 24265722)
1. Functional analysis of a breast cancer-associated FGFR2 single nucleotide polymorphism using zinc finger mediated genome editing.
Robbez-Masson LJ; Bödör C; Jones JL; Hurst HC; Fitzgibbon J; Hart IR; Grose RP
PLoS One; 2013; 8(11):e78839. PubMed ID: 24265722
[TBL] [Abstract][Full Text] [Related]
2. Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.
Meyer KB; O'Reilly M; Michailidou K; Carlebur S; Edwards SL; French JD; Prathalingham R; Dennis J; Bolla MK; Wang Q; de Santiago I; Hopper JL; Tsimiklis H; Apicella C; Southey MC; Schmidt MK; Broeks A; Van 't Veer LJ; Hogervorst FB; Muir K; Lophatananon A; Stewart-Brown S; Siriwanarangsan P; Fasching PA; Lux MP; Ekici AB; Beckmann MW; Peto J; Dos Santos Silva I; Fletcher O; Johnson N; Sawyer EJ; Tomlinson I; Kerin MJ; Miller N; Marme F; Schneeweiss A; Sohn C; Burwinkel B; Guénel P; Truong T; Laurent-Puig P; Menegaux F; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Milne RL; Zamora MP; Arias JI; Benitez J; Neuhausen S; Anton-Culver H; Ziogas A; Dur CC; Brenner H; Müller H; Arndt V; Stegmaier C; Meindl A; Schmutzler RK; Engel C; Ditsch N; Brauch H; Brüning T; Ko YD; ; Nevanlinna H; Muranen TA; Aittomäki K; Blomqvist C; Matsuo K; Ito H; Iwata H; Yatabe Y; Dörk T; Helbig S; Bogdanova NV; Lindblom A; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Chenevix-Trench G; ; ; Wu AH; Tseng CC; Van Den Berg D; Stram DO; Lambrechts D; Thienpont B; Christiaens MR; Smeets A; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Radice P; Peterlongo P; Bonanni B; Bernard L; Couch FJ; Olson JE; Wang X; Purrington K; Giles GG; Severi G; Baglietto L; McLean C; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Simard J; Goldberg MS; Labrèche F; Dumont M; Teo SH; Yip CH; Phuah SY; Kristensen V; Grenaker Alnæs G; Børresen-Dale AL; Zheng W; Deming-Halverson S; Shrubsole M; Long J; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Kauppila S; Andrulis IL; Knight JA; Glendon G; Tchatchou S; Devilee P; Tollenaar RA; Seynaeve CM; García-Closas M; Figueroa J; Chanock SJ; Lissowska J; Czene K; Darabi H; Eriksson K; Hooning MJ; Martens JW; van den Ouweland AM; van Deurzen CH; Hall P; Li J; Liu J; Humphreys K; Shu XO; Lu W; Gao YT; Cai H; Cox A; Reed MW; Blot W; Signorello LB; Cai Q; Pharoah PD; Ghoussaini M; Harrington P; Tyrer J; Kang D; Choi JY; Park SK; Noh DY; Hartman M; Hui M; Lim WY; Buhari SA; Hamann U; Försti A; Rüdiger T; Ulmer HU; Jakubowska A; Lubinski J; Jaworska K; Durda K; Sangrajrang S; Gaborieau V; Brennan P; McKay J; Vachon C; Slager S; Fostira F; Pilarski R; Shen CY; Hsiung CN; Wu PE; Hou MF; Swerdlow A; Ashworth A; Orr N; Schoemaker MJ; Ponder BA; Dunning AM; Easton DF
Am J Hum Genet; 2013 Dec; 93(6):1046-60. PubMed ID: 24290378
[TBL] [Abstract][Full Text] [Related]
3. Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10.
Huijts PE; van Dongen M; de Goeij MC; van Moolenbroek AJ; Blanken F; Vreeswijk MP; de Kruijf EM; Mesker WE; van Zwet EW; Tollenaar RA; Smit VT; van Asperen CJ; Devilee P
Breast Cancer Res; 2011 Jul; 13(4):R72. PubMed ID: 21767389
[TBL] [Abstract][Full Text] [Related]
4. FGFR2 risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness.
Campbell TM; Castro MAA; de Santiago I; Fletcher MNC; Halim S; Prathalingam R; Ponder BAJ; Meyer KB
Carcinogenesis; 2016 Aug; 37(8):741-750. PubMed ID: 27236187
[TBL] [Abstract][Full Text] [Related]
5. Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer.
Zhu X; Asa SL; Ezzat S
Mol Endocrinol; 2009 Sep; 23(9):1397-405. PubMed ID: 19497954
[TBL] [Abstract][Full Text] [Related]
6. A study on genetic variants of Fibroblast growth factor receptor 2 (FGFR2) and the risk of breast cancer from North India.
Siddiqui S; Chattopadhyay S; Akhtar MS; Najm MZ; Deo SV; Shukla NK; Husain SA
PLoS One; 2014; 9(10):e110426. PubMed ID: 25333473
[TBL] [Abstract][Full Text] [Related]
7. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.
Meyer KB; Maia AT; O'Reilly M; Teschendorff AE; Chin SF; Caldas C; Ponder BA
PLoS Biol; 2008 May; 6(5):e108. PubMed ID: 18462018
[TBL] [Abstract][Full Text] [Related]
8. Master regulators of FGFR2 signalling and breast cancer risk.
Fletcher MN; Castro MA; Wang X; de Santiago I; O'Reilly M; Chin SF; Rueda OM; Caldas C; Ponder BA; Markowetz F; Meyer KB
Nat Commun; 2013; 4():2464. PubMed ID: 24043118
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in second intron of the FGFR2 gene are associated with the risk of early-onset breast cancer in Chinese Han women.
Fu F; Wang C; Huang M; Song C; Lin S; Huang H
Tohoku J Exp Med; 2012 Mar; 226(3):221-9. PubMed ID: 22374580
[TBL] [Abstract][Full Text] [Related]
10. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
[TBL] [Abstract][Full Text] [Related]
11. ERα Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signaling to Modulate Estrogen Responsiveness in Breast Cancer.
Campbell TM; Castro MAA; de Oliveira KG; Ponder BAJ; Meyer KB
Cancer Res; 2018 Jan; 78(2):410-421. PubMed ID: 29180470
[TBL] [Abstract][Full Text] [Related]
12. FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation.
Udler MS; Meyer KB; Pooley KA; Karlins E; Struewing JP; Zhang J; Doody DR; MacArthur S; Tyrer J; Pharoah PD; Luben R; Bernstein L; Kolonel LN; Henderson BE; Le Marchand L; Ursin G; Press MF; Brennan P; Sangrajrang S; Gaborieau V; Odefrey F; Shen CY; Wu PE; Wang HC; Kang D; Yoo KY; Noh DY; Ahn SH; Ponder BA; Haiman CA; Malone KE; Dunning AM; Ostrander EA; Easton DF;
Hum Mol Genet; 2009 May; 18(9):1692-703. PubMed ID: 19223389
[TBL] [Abstract][Full Text] [Related]
13. Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer.
Prentice RL; Huang Y; Hinds DA; Peters U; Pettinger M; Cox DR; Beilharz E; Chlebowski RT; Rossouw JE; Caan B; Ballinger DG
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3079-85. PubMed ID: 19861516
[TBL] [Abstract][Full Text] [Related]
14. Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer.
Zhu X; Asa SL; Ezzat S
Am J Pathol; 2010 May; 176(5):2333-43. PubMed ID: 20348248
[TBL] [Abstract][Full Text] [Related]
15. Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.
Frietze S; O'Geen H; Littlepage LE; Simion C; Sweeney CA; Farnham PJ; Krig SR
BMC Genomics; 2014 Jun; 15(1):520. PubMed ID: 24962896
[TBL] [Abstract][Full Text] [Related]
16. Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation.
Ghoussaini M; French JD; Michailidou K; Nord S; Beesley J; Canisus S; Hillman KM; Kaufmann S; Sivakumaran H; Moradi Marjaneh M; Lee JS; Dennis J; Bolla MK; Wang Q; Dicks E; Milne RL; Hopper JL; Southey MC; Schmidt MK; Broeks A; Muir K; Lophatananon A; Fasching PA; Beckmann MW; Fletcher O; Johnson N; Sawyer EJ; Tomlinson I; Burwinkel B; Marme F; Guénel P; Truong T; Bojesen SE; Flyger H; Benitez J; González-Neira A; Alonso MR; Pita G; Neuhausen SL; Anton-Culver H; Brenner H; Arndt V; Meindl A; Schmutzler RK; Brauch H; Hamann U; Tessier DC; Vincent D; Nevanlinna H; Khan S; Matsuo K; Ito H; Dörk T; Bogdanova NV; Lindblom A; Margolin S; Mannermaa A; Kosma VM; ; Wu AH; Van Den Berg D; Lambrechts D; Floris G; Chang-Claude J; Rudolph A; Radice P; Barile M; Couch FJ; Hallberg E; Giles GG; Haiman CA; Le Marchand L; Goldberg MS; Teo SH; Yip CH; Borresen-Dale AL; ; Zheng W; Cai Q; Winqvist R; Pylkäs K; Andrulis IL; Devilee P; Tollenaar RA; García-Closas M; Figueroa J; Hall P; Czene K; Brand JS; Darabi H; Eriksson M; Hooning MJ; Koppert LB; Li J; Shu XO; Zheng Y; Cox A; Cross SS; Shah M; Rhenius V; Choi JY; Kang D; Hartman M; Chia KS; Kabisch M; Torres D; Luccarini C; Conroy DM; Jakubowska A; Lubinski J; Sangrajrang S; Brennan P; Olswold C; Slager S; Shen CY; Hou MF; Swerdlow A; Schoemaker MJ; Simard J; Pharoah PD; Kristensen V; Chenevix-Trench G; Easton DF; Dunning AM; Edwards SL
Am J Hum Genet; 2016 Oct; 99(4):903-911. PubMed ID: 27640304
[TBL] [Abstract][Full Text] [Related]
17. FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: results of a case control study in Japan.
Kawase T; Matsuo K; Suzuki T; Hiraki A; Watanabe M; Iwata H; Tanaka H; Tajima K
Int J Cancer; 2009 Oct; 125(8):1946-52. PubMed ID: 19582883
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of breast cancer susceptibility loci on 2q35, 3p24, 17q23 and FGFR2 genes in Taiwanese women with breast cancer.
Lin CY; Ho CM; Bau DT; Yang SF; Liu SH; Lin PH; Lin TH; Tien N; Shih MC; Lu JJ
Anticancer Res; 2012 Feb; 32(2):475-82. PubMed ID: 22287734
[TBL] [Abstract][Full Text] [Related]
19. Association of polymorphisms in intron 2 of FGFR2 and breast cancer risk in Сhinese women.
Pan Z; Bao Y; Zheng X; Cao W; Cheng W; Xu X
Tsitol Genet; 2016; 50(5):59-64. PubMed ID: 30480917
[TBL] [Abstract][Full Text] [Related]
20. Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.
Kong SL; Li G; Loh SL; Sung WK; Liu ET
Mol Syst Biol; 2011 Aug; 7():526. PubMed ID: 21878914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
